Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm buying Monday if I catch it before it takes off... I sleep a lot
I just want to buy more shares
Never mind... I can't sell short... I never borrow on margin
Cause I'm buying @ .0014
Can u say dilution
Underwater forest management.... Seems like a scam
I'm getting out of this Monday....I don't see it going up...
Buy and ride the wave up then Sell and ride doooown
I'll be waiting to see that 2 mil block
It will go to a dollar..it'll be a bumpy ride thiught
PRESS RELEASE
Nov. 6, 2013, 1:39 p.m. EST
Easton Pharmaceuticals Enters Into Cancer Drug Industry by Acquiring Initial Minority Ownership Interest in Experimental Cancer Drug "XILIVE" With 12 Month Option to Purchase Remaining Interest; Preliminary Feedback Extremely Promising
BELLPORT, NY, Nov 06, 2013 (Marketwired via COMTEX) -- Easton Pharmaceuticals EAPH -13.95% , a specialty pharmaceutical company that designs, develops, and markets an array of topically-delivered drugs and therapeutic healthcare products announced today It has purchased an initial 10 percent ownership interest in experimental cancer drug "XILIVE" From a private Canadian company and individual.
Easton Pharmaceuticals 10 percent cash purchase of "Xilive", an early stage, experimental cancer drug was finalized after completing a conditional financing with an accredited non-affiliated investor with additional funds committed. The purchase agreement for "Xilive" provides the company with an exclusive option to purchase the remaining ownership interest, exercisable anytime over the next 12 month time period.
Xilive is a drug that was developed 7 years ago and utilized under compassionate grounds on two individuals suffering from various forms of advanced stage cancer. The first individual, age 57, suffering from Lymphoma was administered "Xilive" simultaneously with chemotherapy and previously given a 50/50 chance of survival by physicians. The second individual, in his mid 60's, suffering from lung cancer was solely administered "Xilive" after being diagnosed and advised by physicians that the cancer was in its advanced stages where chemotherapy and surgery we're no longer considered a viable medical treatment option. Both individuals have thus far reached and past the critical 5 years or more time period after being diagnosed and advised that their cancers were in remission. One of the individuals suffering from advanced stage lymphoma has been diagnosed cancer free for more than 5 years. Both individuals continue to willingly use "Xilive" as a maintenance and preventative treatment.
In Canada as well as in various states in the United States and most Western European countries, there exist laws that allow for patients diagnosed with terminal cancer or other types of terminal diseases to gain access to experimental drugs for compassionate reasons. Easton Pharmaceuticals and the current majority owner(s) and developers believe "Xilive" can be initially used for a fee under these conditions, which would be concurrent with any type of in-house safety and efficacy trials the company wishes to proceed with. Additional details to be announced.
Regardless of the positive outcomes, neither person was administered "Xilive" under the supervision of any specialized medical physicians. Both Easton Pharmaceuticals and the current majority owner(s) and developers of "Xilive" have not previously, nor are presently claiming "Xilive" positively treated the cancers of these individuals. There have not been any third party independent clinical trials or testing of any form to confirm "Xilive" positively treated and affected these individuals or will be of any future benefit to any other persons diagnosed with any form of cancer or condition who willfully agree to have "Xilive" administered to them as a possible treatment option. Other factors not presently known may have contributed to the dramatic un-expected positive reversal in condition(s).
It is the company's intention to move forward to undertake in-house testing on pre selected cancer patients under the supervision of specialized independent medical physicians prior to formulating a strategy to move the drug to the next level of testing and clinical trials. In-house testing will also need to be finalized prior to any decisions on whether the company exercises its option to purchase any additional ownership interest in "Xilive". Regardless of the amount, if any, the company chooses to additionally purchase of "Xilive", the agreement calls for a 15 percent royalty to be paid to the current majority owner(s) should the drug eventually be proven as safe and effective and reach a stage where it will generate any amount of revenues. Additional news involving details on planned in-house trials and additional committed financing are expected to be announced shortly including the additions of new board members and consultants better specialized in being able to bring such a drug and any testing programs forward.
About Easton Pharmaceuticals Inc
Easton Pharmaceuticals is a specialty pharmaceutical company that designs, develops, and markets what it believes to be a premium array of topically-delivered Drugs and therapeutic healthcare products, focused on Cancer and other health issues related to male and female sexual dysfunction, wound healing, pain, motion sickness, scar and stretch marks, cellulite, varicose veins and other conditions. The company's gel formulation is thought to be an innovative and unique transdermal delivery system. Easton Pharmaceuticals product "VIORRA" is an over-the-counter aid for the treatment to restore and improve vaginal moisture and elasticity which is believed to have a positive effect on women's sexual desire and arousal, FSAD (Female Sexual Arousal Disorder) the world market for these female conditions are in excess of $2 billion. VIORRA is a topical, daily-use product classified by the FDA as containing Generally Recognized as Safe ingredients.
Please read... I've done my research...
Mary j will just be bonus
Plus cancer drug xlive
Easton Pharmaceuticals' first product to market is a female sexual enhancement gel marketed under the brand name ViorraTM. Female Sexual Dysfunction (FSD) is estimated to affect 43% of women, with many women experiencing hypoactive sexual desire disorder (HSDD) or low sex drive at some point in their lives. ViorraTM has been specifically formulated to enhance the female sexual experience with safe and effective vaginal revitalization and increased stimulation.
ViorraTM is an all-natural, hormone free, non-toxic, topical gel that is endorsed by some of the world's leading medical experts on women's sexuality. The doctor recommended daily use of ViorraTM Sensuality Solution helps to restore and improve moisture and vaginal elasticity, improving sexual functioning for women. The improvement of sexual functioning of women has a positive effect on sexual desire, arousal and the ability to experience orgasms. ViorraTM is also designed to be used during sexual intimacy to enhance sexual activity by improving lubrication and providing a warm and pleasurable stimulating sensation. This unique product will be marketed as a premium cosmetic product developed specifically for women interested in maintaining and improving their sexual health and intimate relationships.
Do your dd... They have product... They don't need to be a pot hopefull
I'll sell at 1.00
Climb baby climb
It will climb back up
Just wait till th 14 th
Looks like I'll be buying in to
Would be nice to see .10
Come on .0013
I have 500000 @ .0009
We need 1.40
Boom boom boom
Ok just went through @.0003
I'm trying to buy 500000 @ .0002
Was in @ 0008 sold @ 0012
Don't for today
Dam boards a quite today
I can't find anything that infers this being a pot stock
From the link u posted.... Just be safe
I know but I was able to control your screen... I sent you monif report
Jordan! What what you link to!!!!
Scottrade won't let me buy
Yes but look at Ballard... Plug will drop to that price... Then settle....FedEx will then give it a boost again
Looks like they compete
Plug will go to 1.90 then that's the bottom.... Load up big
Wait a couple of days yet then load up at 1.04
Best wait a couple of days then load up